We used pathCHEMO to elucidate mechanisms of resistance to carboplatin–paclitaxel chemotherapy in lung adenocarcinoma and identified seven molecular pathways implicated in resistance, including chemokine receptors bind chemokines, mRNA splicing, G alpha (s) signalling events, intestinal immune network for IgA production, metabolism of proteins, RNA degradation, and cell cycle mitotic pathways. This evidence concerns the gene CD79A and lung adenocarcinoma.